Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

G-CSF or not G-CSF? That is the question

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ojeda E, Garcia-Bustos J, Aguado MJ et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Blood 1999; 93: 3565.

    CAS  PubMed  Google Scholar 

  2. Faucher C, Le Corroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533–536.

    CAS  Google Scholar 

  3. Cetkovsky P, Koza V, Jindra P et al. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transplant 1997; 20: 639–641.

    Article  CAS  Google Scholar 

  4. Bence-Bruckler I, Bredeson C, Atkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965–969.

    Article  CAS  Google Scholar 

  5. Haylock DN, To LB, Dowse TL et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80: 1405–1414.

    CAS  Google Scholar 

  6. Canales M, Ojeda E, Arrieta R et al. Influence of conditioning regimen on haematopoietic reconstitution in patients following PBPC transplantation. Proc Int Soc Haematol 1997; 88: 88 (abstract P-118).

    Google Scholar 

  7. Ojeda E, Garcia-Bustos J, Aguado MJ et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999; 24: 601–607.

    Article  CAS  Google Scholar 

  8. Lee SM, Radford JA, Dobson L et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294–1299.

    Article  CAS  Google Scholar 

  9. Piccirillo N, Sica S, Laurenti L et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1999; 23: 1245–1250.

    Article  CAS  Google Scholar 

  10. Verma A, Pedicano J, Trifilio S et al. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 2004; 33: 715–719.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Canales, M., Hernández-Navarro, F. G-CSF or not G-CSF? That is the question. Bone Marrow Transplant 34, 557 (2004). https://doi.org/10.1038/sj.bmt.1704615

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704615

Search

Quick links